The Zotect study: Effect of zoledronic acid (Zometa®) on Bone Metabolism in Patients with Nreast or Prostate cancer with Bone metastases.

被引：0
|
作者：
Gschwendt, J. [1 ]
Ziller, M. [2 ]
Kalder, M. [2 ]
Lux, C. [1 ]
Maurer, T. [1 ]
Muth, M. [3 ]
Schmidt, K. [3 ]
Hadji, P. [2 ]
机构：
[1] Klinikum RD Isar, Urol Klin, Munich, Germany
[2] Univ Marburg, Marburg, Germany
[3] Novartis Pharma GmbH, BU Onkol, Nurnberg, Germany
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：204 / 204
页数：1
相关论文
共 50 条
  • [31] Osteonecrosis of the jaw (ONJ) in prostate cancer patients with bone metastases treated with zoledronic acid (Z): A retrospective study
    Ortega, C.
    Montemurro, F.
    Faggiuolo, R.
    Vormola, R.
    Nanni, D.
    Goia, F.
    Gilardino, M. O.
    Aglietta, M.
    ANNALS OF ONCOLOGY, 2006, 17 : XI67 - XI68
  • [32] Bone Turnover Markers as Predictors of Mortality Risk in Prostate Cancer Patients with Bone Metastases Following Treatment with Zoledronic Acid
    Jung, Klaus
    Miller, Kurt
    Wirth, Manfred
    Albrecht, Michael
    Lein, Michael
    EUROPEAN UROLOGY, 2011, 59 (04) : 604 - 612
  • [33] Long-term reduction of bone pain and skeletal morbidity with zoledronic acid in patients with prostate cancer and bone metastases
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (03) : 145 - 145
  • [34] Zoledronic acid provides long-term reduction of bone pain in patients with bone metastases secondary to prostate cancer
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (03) : 144 - 144
  • [35] Prostatic Acid Phosphatase: A Potential Target for Treating Prostate Cancer Bone Metastases.
    Leiter, A. C.
    Kirschenbaum, A.
    Yao, S.
    Levine, A. C.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2012, 60 : S116 - S116
  • [36] Randomized trial of denosumab versus zoledronic acid in prostate cancer patients with bone metastases and elevated bone turnover markers after receiving zoledronic acid therapy
    Bosserman, Linda
    Fizazi, Karim
    Lipton, Allan
    Rahim, Yasmin
    Suarez, Tirzo
    Fan, Michelle
    Wu, Ling
    Markus, Richard A.
    JOURNAL OF UROLOGY, 2007, 177 (04): : 335 - 336
  • [37] Effect of zoledronic acid on bone metabolism in prostate cancer (T3NXMO) patients on the androgen deprivation
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 205 - 205
  • [38] Bone remodeling in relation to androgen receptor activity in prostate cancer bone metastases.
    Ylitalo, Erik Bovinder
    Nordstrand, Annika
    Thysell, Elin
    Jernberg, Emma
    Crnalic, Sead
    Widmark, Anders
    Bergh, Anders
    Lerner, Ulf H.
    Wikstrom, Pernilla
    CANCER RESEARCH, 2018, 78 (16) : 50 - 50
  • [39] NTX and VEGF in cancer patients with bone metastases treated with zoledronic acid
    Mercatali, L.
    Ibrahim, T.
    Sacanna, E.
    Ricci, R.
    Scarpi, E.
    Fabbri, F.
    Serra, P.
    Tison, C.
    Amadori, D.
    EJC SUPPLEMENTS, 2010, 8 (05): : 23 - 23
  • [40] Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases
    Tas, Faruk
    Duranyildiz, Derya
    Oguz, Hilal
    Camlica, Hakan
    Yasasever, Vildan
    Topuz, Erkan
    MEDICAL ONCOLOGY, 2008, 25 (03) : 346 - 349
12345